Coronavirus: cancer patient's urgent plea for treatment in New Zealand

10 August 2020 - A Christchurch cancer patient is missing out on potentially life-saving treatment due to rising COVID-19 cases ...

Read more →

FDA approves first liquid biopsy next generation sequencing companion diagnostic test

7 August 2020 - Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses ...

Read more →

Y-mAbs announces completion of submission of omburtamab biologics license application to FDA

6 August 2020 - Y-mAbs Therapeutics today announced that on 5 August 2020, the Company completed the submission of its biologics ...

Read more →

Darolutamide in prostate cancer: indication of considerable added benefit

3 August 2020 - Advantages in overall survival, symptoms and health-related quality of life. ...

Read more →

FDA approves GSK’s Blenrep (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma

6 August 2020 - Blenrep is the fifth major medicine approval for GSK in 2020. ...

Read more →

The China Center for Drug Evaluation, National Medical Products Administration has recommended breakthrough therapy designation for ciltacabtagene autoleucel, an investigational BCMA CAR-T Cell therapy

5 August 2020 - Legend Biotech announced today that the China Center for Drug Evaluation, National Medical Products Administration has recommended ...

Read more →

Cerecor receives rare paediatric disease designation for CERC-006 in lymphatic malformations

4 August 2020 - Cerecor today announced that the U.S. FDA granted rare paediatric disease designation to CERC-006, a dual inhibitor ...

Read more →

Janssen announces Health Canada approval of Darzalex SC, a new subcutaneous formulation for the treatment of patients with multiple myeloma

4 August 2020 - Darzalex SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in ...

Read more →

Biosight granted U.S. FDA fast track designation for BST-236 for the treatment of acute myeloid leukaemia

4 August 2020 - Biosight today announced that that the U.S. FDA has granted fast track designation for BST-236 (aspacytarabine) ...

Read more →

Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer

3 August 2020 - Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to the brain. ...

Read more →

Schedule of Pharmaceutical Benefits - 1 August 2020

 1 August 2020 - The August 2020 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...

Read more →

FDA approves Monjuvi (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma

31 July 2020 - First FDA approval of a second-line treatment for adult patients with relapsed or refractory diffuse large B-cell ...

Read more →

Australians with cancer, infants with epilepsy to benefit from PBS listings

1 August 2020 - Australians with certain cancers and infants with severe epilepsy will benefit from new medications being listed or ...

Read more →

Medicare expands coverage for BRACAnalysis CDx in prostate cancer

31 July 2020 - Myriad Genetics announced today that Medicare has expanded coverage for BRACAnalysis CDx for men with prostate cancer ...

Read more →

Tagrisso granted breakthrough therapy designation in the US for the adjuvant treatment of patients with Stage IB-IIIA EGFR mutated lung cancer

30 July 2020 - Designation based on unprecedented results from the Phase III ADAURA trial where Tagrisso reduced the risk of ...

Read more →